Provider profile · Multiple program options
Noom Med review: services, costs, and questions
Noom's behavioral and medical weight-management offerings, changing program options, and how to evaluate microdosing claims.
What the official information says
Noom's official Med page describes medication-related weight-management care alongside its behavioral program. Research surfaced more than one program, including offers described as microdose GLP-1 care.
A program label does not identify the medicine, route, dose, or evidence. Ask whether the proposed prescription is FDA-approved for the intended use, and whether a microdosing regimen differs from the approved label.
Sources: Noom Med official program page
Pricing and the full bill
Noom advertises different introductory and recurring program prices across its program pages. This profile does not combine them into a single maintenance price. Get a quote for the exact program, clinical services, medication, and subscription duration; a behavioral subscription may not include the pharmacy bill.
A first-month price is not a reliable annual budget. Ask for the amount charged today, the renewal interval, the cost after any promotion, and whether medication, supplies, visits, labs, and shipping are included. Obtain cancellation and refund terms before paying, particularly if a prescription has not yet been approved.
Sources: Noom Med official program page
Limitations that affect your decision
Microdosing language does not establish that a regimen produces approved-dose weight-loss or prevention benefits. A clinician should explain the rationale and the supporting evidence for the actual medicine and dose.
Behavioral support may be useful to evaluate separately from medication sourcing. We have not measured support quality, app adherence, or outcomes for Noom's enrolled population.
Medication trials evaluate specific formulations, doses, and study populations. A provider advertising semaglutide or tirzepatide has not thereby demonstrated that its own treatment produces the results of Wegovy or Zepbound trials. A compounded medicine is not FDA-approved and should not be described as an approved generic equivalent.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Questions to ask before enrollment
- What does microdose mean for the actual medicine, and which outcomes have been studied at that dose?
- Which subscription and pharmacy charges continue after the introductory period?
- What exact medicine, formulation, and device would I receive, and which pharmacy dispenses it?
- Who prescribes in my state, and how do I obtain urgent clinical help?
- What will I pay at maintenance, and when do renewals and cancellation deadlines occur?
Ask the prescribing clinician how your other medicines, diabetes treatment, pregnancy plans, gastrointestinal history, and follow-up needs affect eligibility. Check the dispensing pharmacy with the relevant state board. A reassuring website or testimonial does not replace those checks.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
The engagement footnote limits the outcome claim
Noom's page promotes greater weight loss with the program and cites a January 2026 analysis of 14,203 GLP-1Rx members who actively logged weight over a 40-week period. Its footnote describes groups based on app engagement and an association with greater loss at 16 weeks, explicitly saying that association does not imply causation. That is materially different from a randomized comparison isolating the effect of the program.
Ask how inclusion, missing follow-up, discontinuation, and medication choice affect the advertised figure. A relative statement such as "37% more" also should not be mistaken for losing 37% of starting body weight. Behavioral tools may be a useful feature to assess, but the public analysis cannot promise a particular result for a new enrollee or prove that engagement alone caused the difference. We have not independently audited the underlying program data.
Sources: Noom Med official program page
Assess Muscle Defense and microdosing as specific claims
The page advertises muscle-related support and personalized dosing. Ask what services that includes: dietitian access, individualized food planning, a structured activity plan, functional assessment, or app content. A branded support name does not establish that every patient preserves muscle. The joint nutrition advisory emphasizes both adequate nourishment and strength activity, with individual assessment.
For microdosing, request the exact regimen, intended outcome, and evidence at the offered dose and formulation. A low dose is not automatically a preventive treatment or free of contraindications and interactions. Also ask who reviews symptoms and refills, how medication delivery works for your insurance or self-pay route, and what happens during a pause. Compare those documented services and the complete bill rather than a program name or the largest headline percentage.
Sources: Noom Med official program page · Joint advisory: nutritional priorities to support GLP-1 therapy for obesity · Wegovy prescribing information, including tablets and Wegovy HD · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Provider sources support advertised services and terms. Clinical and regulatory sources explain medication and pharmacy considerations. These are distinct kinds of evidence.